Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 13/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933809 | 0.94 | PTK6 (0.45) | PTK6HRH4HRH3LCKAURKB | |
| Trifluoroacetic Acid SCHEMBL2932757 | 0.85 | KDR (0.46) | PTK6HRH4HRH3AURKBKDR | |
| SCHEMBL2928708 | 0.81 | BRAF (0.39) | KDR | |
| SCHEMBL2927739 | 0.78 | KDR (0.51) | PTK6HRH4HRH3AURKBKDR | |
| Trifluoroacetic Acid SCHEMBL2930403 | 0.76 | CDK2 (0.41) | PTK6HRH4AURKBKDR | |
| Trifluoroacetic Acid SCHEMBL2933810 | 0.76 | LRRK2 (0.49) | — | |
| SCHEMBL2931626 | 0.74 | BRAF (0.39) | AURKBKDRSYK | |
| Trifluoroacetic Acid SCHEMBL2931238 | 0.74 | ATR (0.45) | HRH3KDRATR | |
| Trifluoroacetic Acid SCHEMBL2927386 | 0.74 | ATR (0.45) | HRH3KDRATR | |
| SCHEMBL2928571 | 0.73 | BTK (0.53) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PTK6 341/4885HRH4 1833/4885HRH3 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.